Mabwell(SH:688062)2023-11-30 08:40Group 1: Clinical Data and Drug Efficacy - The latest clinical data for Nectin-4 ADC (9MW2821) shows an overall response rate (ORR) of 43.5% and a disease control rate (DCR) of 81.7% among 115 evaluable solid tumor patients [5] - In the 1.25 mg/kg dose group for urothelial carcinoma, the ORR reached 62.2% and the DCR was 91.9% [5] - For cervical cancer, the ORR was reported at 50% and the DCR at 100% in a preliminary study involving 6 evaluable patients [7] Group 2: Market Potential and Growth - The osteoporosis patient population in China exceeds 300 million, with a prevalence rate of 19.2% among individuals over 50 years old [11] - The market for denosumab (迈利舒®) in osteoporosis is projected to reach RMB 7.82 billion by 2030, driven by increased accessibility and favorable clinical outcomes [11] - The company anticipates achieving breakeven or profitability through multiple product lines, including upcoming launches from 2023 to 2026 [14] Group 3: Pipeline and Development - The company has 14 pipeline projects, with 10 being innovative drugs, and is focusing on international collaborations for products like anti-Nectin-4 ADC and anti-B7-H3 ADC [14] - The company is actively pursuing clinical trials for 9MW3811, a monoclonal antibody targeting IL-11, which is currently in Phase I trials in China, Australia, and the US [13] - The ADC platform includes three innovative products in clinical stages: Nectin-4 ADC (9MW2821), Trop-2 ADC (9MW2921), and B7-H3 ADC (7MW3711) [9]